Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Heart Failure Reports
Erschienen in: Current Heart Failure Reports 4/2020

06.06.2020 | Devices (C Veltmann, Section Editor)

CRT-Pacemaker Versus CRT-Defibrillator Who Needs Sudden Cardiac Death Protection?

verfasst von: Vincent Galand, Raphaël P. Martins, Nathalie Behar, Camille Pichard, Philippe Mabo, Christophe Leclercq

Erschienen in: Current Heart Failure Reports | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of the Review

Patients with cardiomyopathy and impaired left ventricular (LV) ejection fraction are at risk of sudden cardiac death (SCD). In selected heart failure patients, cardiac resynchronization therapy (CRT) provides LV reverse remodeling and improves the cellular and molecular function leading to a reduced risk of ventricular arrhythmia and SCD. Consequently, some CRT candidates may not need concomitant ICD therapy. This review aimed at focusing on the residual risk of SCD in patients receiving CRT and discussing the requirement of a concomitant ICD therapy in CRT candidates.

Recent Findings

New imaging diagnostic tools may be helpful to accurately predict patient with a residual risk of SCD and who required a CRT-D implantation. Recent data highlighted that cardiac computed tomography (CT) or myocardial scar tissue analysis using contrast-enhanced cardiac magnetic resonance (CMR) was able to predict the occurrence of VA in patients with bi-ventricular pacing.

Summary

Cardiac imaging and specifically myocardial scar analysis seem promising to evaluate the risk of SCD following bi-ventricular pacing and will probably be of great help in the future to accurately identify those who needs concomitant defibrillator’s protection.
Literatur
1.
Khand A, Gemmel I, Clark AL, Cleland JGF. Is the prognosis of heart failure improving? J Am Coll Cardiol. 2000;36:2284–6.PubMed
2.
Kreuz J, Horlbeck F, Linhart M, Mellert F, Fimmers R, Schrickel J, et al. Independent predictors of mortality in patients with advanced heart failure treated by cardiac resynchronization therapy. Europace. 2012;14:1596–601.PubMed
3.
Cazeau S, Leclercq C, Lavergne T, Walker S, Varma C, Linde C, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med. 2001;344(12):873–80.PubMed
4.
Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346(24):1845–53.PubMed
5.
Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352(15):1539–49.PubMed
6.
Daubert C, Gold MR, Abraham WT, Ghio S, Hassager C, Goode G, et al. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial. J Am Coll Cardiol. 2009;54(20):1837–46.PubMed
7.
Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361(14):1329–38.PubMed
8.
Birnie DH, Ha A, Higginson L, Sidhu K, Green M, Philippon F, et al. Impact of QRS morphology and duration on outcomes after cardiac resynchronization therapy: results from the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT). Circ Heart Fail. 2013;6(6):1190–8.PubMed
9.
Aiba T, Hesketh GG, Barth AS, Liu T, Daya S, Chakir K, et al. Electrophysiological consequences of dyssynchronous heart failure and its restoration by resynchronization therapy. Circulation. 2009;119:1220–30.PubMedPubMedCentral
10.
Iyengar S, Haas G, Lamba S, Orsinelli DA, Babu GJ, Ferketich AK, et al. Effect of cardiac resynchronization therapy on myocardial gene expression in patients with nonischemic dilated cardiomyopathy. J Card Fail. 2007;13:304–11.PubMed
11.
Barsheshet A, Wang PJ, Moss AJ, Solomon SD, Al-Ahmad A, McNitt S, et al. Reverse remodeling and the risk of ventricular tachyarrhythmias in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy). J Am Coll Cardiol. 2011;57(24):2416–23.PubMed
12.
Killu AM, Mazo A, Grupper A, Madhavan M, Webster T, Brooke KL, et al. Super-response to cardiac resynchronization therapy reduces appropriate implantable cardioverter defibrillator therapy. Europace. 2018;20:1303–11.PubMed
13.
Van der Heijden AC, Höke U, Thijssen J, Borleffs CJ, van Rees JB, van der Velde ET, et al. Super-responders to cardiac resynchronization therapy remain at risk for ventricular arrhythmias and benefit from defibrillator treatment. Eur J Heart Fail. 2014;16(10):1104–11.PubMed
14.
• Leyva F, Zegard A, Acquaye E, Gubran C, Taylor R, Foley PWX, et al. Outcomes of cardiac resynchronization therapy with or without defibrillation in patients with nonischemic cardiomyopathy. J Am Coll Cardiol. 2017;70(10):1216–27. This study provides important information about the impact of myocardial mid wall fibrosis on outcomes in non-ischemic patients receiving CRT.PubMed
15.
Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt OA, et al. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J. 2013;34:2281–329.PubMed
16.
Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140–50.PubMed
17.
Theuns DAMJ, Smith T, Hunink MGM, Bardy GH, Jordaens L. Effectiveness of prophylactic implantation of cardioverter-defibrillators without cardiac resynchronization therapy in patients with ischaemic or non-ischaemic heart disease: a systematic review and meta-analysis. Europace. 2010;12:1564–70.PubMedPubMedCentral
18.
Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter–defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–37.PubMed
19.
Packer DL, Prutkin JM, Hellkamp AS, Mitchell LB, Bernstein RC, Wood F, et al. Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. Circulation. 2009;120:2170–6.PubMedPubMedCentral
20.
Santangeli P, Rame JE, Birati EY, Marchlinski FE. Management of ventricular arrhythmias in patients with advanced heart failure. J Am Coll Cardiol. 2017;69(14):1842–60.PubMed
21.
Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225–37.PubMed
22.
Vanderheyden M, Mullens W, Delrue L, Goethals M, de Bruyne B, Wijns W, et al. Myocardial gene expression in heart failure patients treated with cardiac resynchronization therapy responders versus nonresponders. J Am Coll Cardiol. 2008;51(2):129–36.PubMed
23.
Wang J, Gong X, Chen H, Qin S, Zhou N, Su Y, et al. Effect of cardiac resynchronization therapy on myocardial fibrosis and relevant cytokines in a canine model with experimental heart failure. J Cardiovasc Electrophysiol. 2017;28(4):438–45.PubMed
24.
Wang J, Gong X, Chen H, et al. Effect of cardiac resynchronization therapy on myocardial fibrosis and relevant cytokines in a canine model with experimental heart failure. J Cardiovasc Electrophysiol. 2017;28(4):438–45.PubMed
25.
St John Sutton MG, Plappert T, Abraham WT, Smith AL, DeLurgio DB, Leon AR, et al. Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation. 2003;107(15):1985–90.PubMed
26.
Galand V, Ghoshhajra B, Szymonifka J, Leclercq C, Truong QA, Singh JP. Computed tomography-guided assessment of response to cardiac resynchronization therapy. JACC Clin Electrophysiol. 2019;5(8):987–9.PubMed
27.
Chung ES, Leon AR, Tavazzi L, Sun JP, Nihoyannopoulos P, Merlino J, et al. Results of the predictors of response to CRT (PROSPECT) trial. Circulation. 2008;117(20):2608–16.PubMed
28.
Prinzen FW, Vernooy K, Auricchio A. Cardiac resynchronization therapy: state-of-the-art of current applications, guidelines, ongoing trials, and areas of controversy. Circulation. 2013;128(22):2407–18.PubMed
29.
Stankovic I, Belmans A, Prinz C, et al. The association of volumetric response and long-term survival after cardiac resynchronization therapy. Eur Heart J Cardiovasc Imaging. 2017;18(10):1109–17.PubMed
30.
Hsu JC, Solomon SD, Bourgoun M, McNitt S, Goldenberg I, Klein H, et al. Predictors of super-response to cardiac resynchronization therapy and associated improvement in clinical outcome: the MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy) study. J Am Coll Cardiol. 2012;59(25):2366–73.PubMed
31.
Vaillant C, Martins RP, Donal E, Leclercq C, Thébault C, Behar N, et al. Resolution of left bundle branch block-induced cardiomyopathy by cardiac resynchronization therapy. J Am Coll Cardiol. 2013;61(10):1089–95.PubMed
32.
Amara N, Boveda S, Defaye P, et al. Implantable cardioverter-defibrillator therapy among patients with non-ischaemic vs. ischaemic cardiomyopathy for primary prevention of sudden cardiac death. Europace. 2018;20(1):65–72.PubMed
33.
Marijon E, Leclercq C, Narayanan K, Boveda S, Klug D, Lacaze-Gadonneix J, et al. Causes-of-death analysis of patients with cardiac resynchronization therapy: an analysis of the CeRtiTuDe cohort study. Eur Heart J. 2015;36(41):2767–76.PubMedPubMedCentral
34.
35.
Arya A, Haghjoo M, Dehghani MR, Alasti M, Alizadeh H, Kazemi B, et al. Effect of cardiac resynchronization therapy on the incidence of ventricular arrhythmias in patients with an implantable cardioverter-defibrillator. Heart Rhythm. 2005;2(10):1094–8.PubMed
36.
Ouellet G, Huang DT, Moss AJ, Hall WJ, Barsheshet A, McNitt S, et al. Effect of cardiac resynchronization therapy on the risk of first and recurrent ventricular tachyarrhythmic events in MADIT-CRT. J Am Coll Cardiol. 2012;60(18):1809–16.PubMed
37.
Ruwald MH, Solomon SD, Foster E, Kutyifa V, Ruwald AC, Sherazi S, et al. Left ventricular ejection fraction normalization in cardiac resynchronization therapy and risk of ventricular arrhythmias and clinical outcomes: results from the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) trial. Circulation. 2014;130(25):2278–86.PubMed
38.
Chatterjee NA, Roka A, Lubitz SA, Gold MR, Daubert C, Linde C, et al. Reduced appropriate implantable cardioverter-defibrillator therapy after cardiac resynchronization therapy-induced left ventricular function recovery: a meta-analysis and systematic review. Eur Heart J. 2015;36(41):2780–9.PubMedPubMedCentral
39.
Zhang Y, Guallar E, Blasco-Colmenares E, Butcher B, Norgard S, Nauffal V, et al. Changes in followup left ventricular ejection fraction associated with outcomes in primary prevention implantable cardioverter-defibrillator and cardiac resynchronization therapy device recipients. J Am Coll Cardiol. 2015;66:524–31.PubMedPubMedCentral
40.
García-Lunar I, Castro-Urda V, Toquero-Ramos J, Mingo-Santos S, Moñivas-Palomero V, Daniela Mitroi C, et al. Ventricular arrhythmias in super-responders to cardiac resynchronization therapy. Rev Esp Cardiol (Engl Ed). 2014;67(11):883–9.
41.
García-Lunar I, Castro-Urda V, Toquero-Ramos J, Mingo-Santos S, Moñivas-Palomero V, Daniela Mitroi C, et al. Ventricular arrhythmias in super-responders to cardiac resynchronization therapy. Rev Esp Cardiol (Engl Ed). 2014;67(11):883–9.
42.
Loughlin G, Avila P, Martinez-Ferrer JB, Alzueta J, Vinolas X, Brugada J, et al. Association of cardiac resynchronization therapy with the incidence of appropriate implantable cardiac defibrillator therapies in ischaemic and non-ischaemic cardiomyopathy. Europace. 2017;19(11):1818–25.PubMed
43.
Fernández-Armenta J, Berruezo A, Mont L, Sitges M, Andreu D, Silva E, et al. Use of myocardial scar characterization to predict ventricular arrhythmia in cardiac resynchronization therapy. Europace. 2012;14(11):1578–86.PubMed
44.
Leyva F, Zegard A, Umar F, Taylor RJ, Acquaye E, Gubran C, et al. Long term clinical outcomes of cardiac resynchronization therapy with or without defibrillation: impact of the aetiology of cardiomyopathy. Europace. 2018;20(11):1804–12.PubMedPubMedCentral
45.
Drozd M, Gierula J, Lowry JE, Paton MF, Joy E, Jamil HA, et al. Cardiac resynchronization therapy outcomes in patients with chronic heart failure: cardiac resynchronization therapy with pacemaker versus cardiac resynchronization therapy with defibrillator. Cardiovasc Med (Hagerstown). 2017;18(12):962–7.
46.
Auricchio A, Fantoni C, Regoli F, Carbucicchio C, Goette A, Geller C, et al. Characterization of left ventricular activation in patients with heart failure and left bundle-branch block. Circulation. 2004;109(9):1133–9.PubMed
47.
Skalidis EI, Kochiadakis GE, Koukouraki SI, Parthenakis FI, Karkavitsas NS, Vardas PE. Phasic coronary flow pattern and flow reserve in patients with left bundle branch block and normal coronary arteries. J Am Coll Cardiol. 1999;33(5):1338–46.PubMed
48.
Auffret V, Martins RP, Daubert C, Leclercq C, Le Breton H, Mabo P, et al. Idiopathic/iatrogenic left bundle branch block-induced reversible left ventricle dysfunction: JACC State-of-the-Art Review. J Am Coll Cardiol. 2018;72(24):3177–88.PubMed
49.
Auffret V, Puri R, Urena M, Chamandi C, Rodriguez-Gabella T, Philippon F, et al. Conduction disturbances after transcatheter aortic valve replacement: current status and future perspectives. Circulation. 2017;136:1049–69.PubMed
50.
Testa L, Latib A, De Marco F, et al. Clinical impact of persistent left bundle-branch block after transcatheter aortic valve implantation with CoreValve revalving system. Circulation. 2013;127:1300–7.PubMed
51.
Urena M, Mok M, Serra V, Dumont E, Nombela-Franco L, DeLarochellière R, et al. Predictive factors and long-term clinical consequences of persistent left bundle branch block following transcatheter aortic valve implantation with a balloon-expandable valve. J Am Coll Cardiol. 2012;60:1743–52.PubMed
52.
Galand V, Ghoshhajra B, Szymonifka J, Das S, Orencole M, Barré V, et al. Left ventricular wall thickness assessed by cardiac computed tomography and cardiac resynchronization therapy outcomes. Europace. 2020;22(3):401–11.PubMed
53.
Galand V, Ghoshhajra B, Szymonifka J, Das S, Leclercq C, Martins RP, et al. Utility of computed tomography to predict ventricular arrhythmias in patients with nonischemic cardiomyopathy receiving cardiac resynchronization therapy. Am J Cardiol. 2020;125(4):607–12.PubMed
54.
Ustunkaya T, Desjardins B, Liu B, Zahid S, Park J, Saju N, et al. Association of regional myocardial conduction velocity with the distribution of hypoattenuation on contrast-enhanced perfusion computed tomography in patients with post-infarct ventricular tachycardia. Heart Rhythm. 2019;16(4):588–94.PubMed
55.
Leyva F, Taylor RJ, Foley PW, Umar F, Mulligan LJ, Patel K, et al. Left ventricular midwall fibrosis as a predictor of mortality and morbidity after cardiac resynchronization therapy in patients with nonischemic cardiomyopathy. J Am Coll Cardiol. 2012;60(17):1659–67.PubMed
56.
Fernández-Armenta J, Berruezo A, Mont L, et al. Use of myocardial scar characterization to predict ventricular arrhythmia in cardiac resynchronization therapy. Europace. 2012;14(11):1578–86.PubMed
57.
• Acosta J, Fernández-Armenta J, Borràs R, Anguera I, Bisbal F, Martí-Almor J, et al. Scar characterization to predict life-threatening arrhythmic events and sudden cardiac death in patients with cardiac resynchronization therapy: the GAUDI-CRT Study. JACC Cardiovasc Imaging. 2018;11(4):561–72. This study provides an extensive description of how myocardial characterization using MRI can predict the risk SDC after CR implantation.PubMed
58.
Bilchick KC, Auger DA, Abdishektaei M, Mathew R, Sohn MW, Cai X, et al. CMR DENSE and the Seattle Heart Failure Model inform survival and arrhythmia risk after CRT. JACC Cardiovasc Imaging. 2020;13(4):924–36.PubMed
Metadaten
Titel
CRT-Pacemaker Versus CRT-Defibrillator Who Needs Sudden Cardiac Death Protection?
verfasst von
Vincent Galand
Raphaël P. Martins
Nathalie Behar
Camille Pichard
Philippe Mabo
Christophe Leclercq
Publikationsdatum
06.06.2020
Verlag
Springer US
Erschienen in
Current Heart Failure Reports / Ausgabe 4/2020
Print ISSN: 1546-9530
Elektronische ISSN: 1546-9549
DOI
https://doi.org/10.1007/s11897-020-00465-z

Weitere Artikel der Ausgabe 4/2020

Current Heart Failure Reports 4/2020 Zur Ausgabe

Nonpharmacologic Therapy: Surgery, Ventricular Assist Devices, Biventricular Pacing, and Exercise (A Hasan, Section Editor)

Continuous-Flow Left Ventricular Assist Devices and the Aortic Valve: Interactions, Issues, and Surgical Therapy

Nonpharmacologic Therapy: Surgery, Ventricular Assist Devices, Biventricular Pacing, and Exercise (A Hasan, Section Editor)

Contemporary Management Strategies in VAD Infection

Biomarkers of Heart Failure (WH Tang & J Grodin, Section Editors)

Impact of Sacubitril-Valsartan on Markers of Glomerular Function

Ethics/Palliative Care (S Fedson, Section Editor)

Ethical Challenges in Care of Patients on Mechanical Circulatory Support at End-of-Life

Nonpharmacologic Therapy: Surgery, Ventricular Assist Devices, Biventricular Pacing, and Exercise (A Hasan, Section Editor)

Hepatitis C–Positive Donors in Cardiac Transplantation: Problems and Opportunities

Devices (C Veltmann, Section Editor)

The Role of Wearables in Heart Failure

Neu im Fachgebiet Kardiologie

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

10.05.2024 Periphere arterielle Verschlusskrankheit Nachrichten

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise